https://www.selleckchem.com/products/ml-7.html
ing that combined biomarkers would be of great value for the design of personalized treatments. This was a single institute, phase I/II study of salvage chemoradiotherapy (CRT) with simultaneous integrated boost in patients with mediastinal lymph node (LN) recurrence after esophagectomy. Patients who presented with a clinical diagnosis of ≤5 mediastinal LN recurrence received three consecutive levels of radiotherapy dose for the recurrences. Level 1 58.8 Gy/2.1 Gy/28 fractions, Level 2 64.4 Gy/2.3 Gy/28 fractions and Level 3 70 Gy/2.5 Gy/2
Like
Comment
Share
